Market Intelligence, Clinical Progress, and High-Purity Reagents for Vascular Barrier and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for VE-cadherin (CDH5) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDH5 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View CDH5 Products |
| Gene Delivery | CDH5 Promise-ORF / Lentivirus Full-length human CDH5 ORF for stable endothelial-like cell line construction. |
View CDH5 Products |
| Benchmark Ab | Anti-CDH5 Recombinant Antibody Recombinant positive control derived from clinical/preclinical benchmark clones (e.g., BV13 / E4G10 sequence). |
View CDH5 Products |
| Validator | CDH5 siRNA Set Target-specific siRNA pool for knockdown verification in endothelial barrier assays. |
View CDH5 Products |
| Related Target A | VE-PTP (PTPRB) Crucial phosphatase regulating VE-cadherin phosphorylation and junction stability. |
View PTPRB Products |
| Related Target B | VEGFR2 (KDR) Synergistic pathway partner; VEGF-induced VEGFR2 activation triggers VE-cadherin internalization. |
View KDR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homophilic binding assay optimization | HEK293-expressed CDH5 ECD-Fc preserves native calcium-dependent conformation required for homophilic interaction. |
| Cross-species reactivity screening | Human, Mouse, and Cynomolgus CDH5 ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live VE-cadherin (CDH5) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of VE-cadherin (CDH5) is undergoing a major paradigm shift. Historically pursued as an oncology target to disrupt tumor angiogenesis and vascular mimicry, modern R&D is heavily focusing on its role as the gatekeeper of endothelial barrier integrity. Biotechs are actively developing two opposing classes of therapeutics: antagonistic monoclonal antibodies/ADCs to destroy tumor vasculature, and stabilizing/agonistic molecules (often targeting the VE-cadherin/VE-PTP axis) to treat systemic vascular leak, acute respiratory distress syndrome (ARDS), diabetic macular edema, and ophthalmic disorders.
"The race for VE-cadherin therapeutics is intensifying, with major players shifting focus from traditional systemic disruption to localized barrier stabilization and highly targeted ADCs. As first-generation vascular-disrupting agents reach clinical maturity, the next wave of R&D is targeting the fine-tuning of junctional kinetics to prevent systemic edema while maximizing localized efficacy."
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Antagonistic) | Oncology biotechs, Academic consortia | Solid Tumors, Angiosarcoma | Homophilic binding inhibition assays (Requires conformationally intact CDH5 ECD-Fc) |
| Antibody-Drug Conjugates (ADC) | Clinical-stage oncology pipelines | Vascular-rich metastatic tumors | Internalization assays (Requires high-purity ECD-Fc and stable CDH5-expressing cell lines) |
| Barrier Stabilizers / Bispecifics | Aerami Therapeutics, Roche, Ophthalmic specialists | ARDS, Diabetic Retinopathy, Wet AMD | Co-receptor binding kinetics (Requires CDH5 and VE-PTP/PTPRB co-validation panels) |